Alpelisib (targeting the PI3K catalyst subunit α or PI3KCA) and everolimus (targeting mTOR) are already approved by the FDA for the treatment of HR-positive, HER2-negative breast cancers (with a PIK3CA mutation for alpelisib). Here, MTOR is linked to breast carcinoma.